Protalix BioTherapeutics to Present at Upcoming Scientific and Medical Meetings

Protalix BioTherapeutics to Present at Upcoming Scientific and Medical
Meetings

CARMIEL, Israel, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE MKT:PLX) (TASE:PLX), today announced that data from select pipeline
candidates and information on the Company's plant cell based technology,
ProCellEx®, will be presented at upcoming scientific and medical meetings.
Details regarding the conferences are as follows:

64^th Annual Meeting of American Association for the Study of Liver Diseases,
November 1-5, 2013, Walter E. Washington Convention Center, Washington, DC.

  oPoster entitled, "Oral administration of a plant cell-expressed
    recombinant anti-TNF fusion protein is biologically active in the gut and
    alleviates immune mediated hepatitis," to be presented, November 3, 2013
    from 8:00 AM – 5:30 PM ET

A copy of the poster will be posted on the Company's website.

Brazil's Ministry of Health- Fiocruz Plant Based Technology Meeting, November
21-22, 2013 in Fortaleza, Ceará, Brazil.The objectives of this meeting, which
will be chaired by Brazil's Minister of Health and Fiocruz's president, are to
discuss trends about plant based technologies, partnerships, raise awareness
among the various stakeholders about plant-based technologies and disseminate
information about Bio-Manguinhos/Fiocruz's new facilities at Ceará for
plant-based technologies.

  oProtalix oral presentation on Plant Cell Culture to be given November 21,
    2013 at 4:00 PM BRT

About Protalix

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell-based expression system, ProCellEx®.Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.Protalix's first
product manufactured by ProCellEx, taliglucerase alfa, was approved for
marketing by theU.S. Food and Drug Administration (FDA) inMay 2012,
byIsrael'sMinistry of HealthinSeptember 2012, by theBrazilian National
Health Surveillance Agency(ANVISA) inMarch 2013, by theMexican Federal
Commission for the Protection against Sanitary Risk (COFEPRIS) inApril 2013,
and by the regulatory authorities of other countries.Marketing applications
for taliglucerase alfa have been filed in additional territories as well.
Protalix has partnered withPfizer Inc.for the worldwide development and
commercialization of taliglucerase alfa, excludingIsraelandBrazil, where
Protalix retains full rights. Protalix's development pipeline also includes
the following product candidates: PRX-102, a modified version of the
recombinant human alpha-GAL-A protein for the treatment of Fabry disease;
PRX-105, a pegylated recombinant human acetylcholinesterase in development for
several therapeutic and prophylactic indications, a biodefense program and an
organophosphate-based pesticide treatment program; an orally-delivered
glucocerebrosidase enzyme that is produced and encapsulated within carrot
cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant
cell version of etanercept (Enbrel®) for the treatment of certain immune
diseases such as rheumatoid arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; PRX-110 for
the treatment of Cystic Fibrosis; PRX-107 for the treatment of emphysema due
to hereditary alpha1-antitrypsin deficiency; and others.

Forward-Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe-harbor provisions of the Private Securities Litigation Reform Act of
1995. The terms "anticipate," "believe," "estimate," "expect," "plan" and
"intend" and other words or phrases of similar import are intended to identify
forward-looking statements.Drug discovery and development involve a high
degree of risk.Factors that might cause material differences include, among
others: failure or delay in the commencement or completion of our preclinical
studies and clinical trials which may be caused by several factors, including:
unforeseen safety issues; determination of dosing issues; lack of
effectiveness during clinical trials; slower than expected rates of patient
recruitment; inability to monitor patients adequately during or after
treatment; inability or unwillingness of medical investigators and
institutional review boards to follow our clinical protocols; lack of
sufficient funding to finance the clinical trials; the risk that the results
of our clinical trials will not support the applicable claims of safety or
efficacy, that our product candidates will not have the desired effects or
will include undesirable side effects or other unexpected characteristics; our
dependence on performance by third-party providers of services and supplies,
including without limitation, clinical trial services; delays in our
preparation and filing of applications for regulatory approval; delays in the
approval or potential rejection of any applications we file with theFDA or
other health regulatory authorities; the inherent risks and uncertainties in
developing drug platforms and products of the type we are developing; the
impact of development of competing therapies and/or technologies by other
companies and institutions; potential product liability risks; and other
factors described in our filings with theU.S. Securities and Exchange
Commission.These forward-looking statements are based on current information
that may change and you are cautioned not to place undue reliance on these
forward-looking statements. The statements in this release are valid only as
of the date hereof and we disclaim any obligation to update this information.
All forward-looking statements are qualified in their entirety by this
cautionary statement.

CONTACT: Investor Contact
         Marcy Nanus
         The Trout Group, LLC
         646-378-2927
         mnanus@troutgroup.com
         Media Contact
         Kari Watson
         MacDougall Biomedical Communications
         781-235-3060
         kwatson@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.